← Eichor
Study identifier: NCT07306741 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Cognitive and Fusion Prostatic Biopsy

Condition: Prostate Cancer  ·  Sponsor: Menoufia University

PhaseNA
Planned participants80
Who can joinMale, N/A to no upper limit
Healthy volunteersNo

About this study

The goal of this study is to compare two different prostate biopsy techniques used to detect prostate cancer. These techniques are cognitive-targeted biopsy (CTB) and magnetic resonance imaging-ultrasound fusion-targeted transrectal biopsy (FTB). Both methods aim to improve the accuracy of prostate cancer detection by targeting suspicious areas identified on prostate imaging. This study will compare how accurately each technique detects prostate cancer, the pathological findings obtained from each biopsy method, and how operator performance may influence the procedure. The information gained from this study may help improve prostate cancer diagnosis and guide future biopsy practices.

This description comes directly from the study's public registry record.

Talk to the study team

Mahmoud A Wahbah, MASTER  ·  00201015684868  ·  mwahbah4@gmail.com

Always discuss trial participation with your own doctor first.

Locations (2)

Menoufia university hospital urology departmentShibīn al Kawm, EgyptNot Yet Recruiting
Menoufia university hospital urology departmentShibīn al Kawm, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07306741